You are here:
Questions and Answers about Raynaud’s Phenomenon
This publication contains general information about Raynaud’s phenomenon. It describes what Raynaud’s phenomenon is, who gets it, and what happens during an attack. It also explains how Raynaud’s phenomenon is diagnosed and treated. At the end is a list of key words to help you understand the terms used in this publication. If you have further questions after reading this publication, you may wish to discuss them with your doctor.
What Is Raynaud’s Phenomenon?
Raynaud’s phenomenon is a condition that affects the blood vessels in the extremities—generally, the fingers and toes. It is characterized by episodic attacks, called vasospastic attacks, in which the blood vessels in the digits (fingers and toes) constrict (narrow), usually in response to cold temperatures and/or emotional stress. When this condition occurs on its own, it is called primary Raynaud’s phenomenon. When it occurs with another condition such as scleroderma or lupus, it is called secondary Raynaud’s phenomenon.
Although people of any age can have Raynaud’s phenomenon, the primary form typically begins before the age of 30 and often runs in families. Women are more likely than men to have Raynaud’s phenomenon. It appears to be more common in people who live in colder climates. This is likely true because people with the disorder have more Raynaud’s attacks during periods of colder weather. For most, the symptoms are mild and not associated with any blood vessel or tissue damage.
Most people with Raynaud’s phenomenon have the primary form, which is not associated with any underlying disease. In fact, in these individuals it is thought to be an exaggeration of normal responses to cold temperature and/or stress.
When Raynaud’s phenomenon is caused by or associated with an underlying disease, it is referred to as secondary Raynaud’s phenomenon. Secondary Raynaud’s phenomenon tends to begin later in life than the primary form.
It is common for patients with a connective tissue disease to have Raynaud’s phenomenon. It occurs in more than 90 percent of people with scleroderma. It is also common in people with systemic lupus erythematosus, rheumatoid arthritis, and Sjögren’s syndrome. Secondary Raynaud’s phenomenon may also be associated with diseases of the arteries, smoking, and overuse and other injuries that cause trauma to the hands and wrists. And it may be linked to certain drugs such as chemotherapy agents or to chemicals such as vinyl chloride.
Attacks of Raynaud’s phenomenon are caused by an intensification of the body’s natural response to cold. When a person is exposed to cold, the body’s normal response is to slow the loss of heat and preserve its core temperature. Blood vessels in the surface of the skin are called thermoregulatory vessels because they react to changes in the ambient temperature. To maintain normal core temperature, these specialized blood vessels in the skin surface constrict and move blood from arteries near the surface to veins deeper in the body. But for people who have Raynaud’s phenomenon, the thermoregulatory vessels overreact to cold exposure with sudden and intense spasmodic contractions of these small blood vessels that supply blood to the skin of the fingers, toes, ears, face, and other body areas.
Once an attack begins, a person may experience three phases (though not all people have all three) of skin color changes—typically from white to blue to red—in the fingers or toes. Whiteness (called pallor) may occur in response to spasms of the arterioles (small branches of an artery) and the resulting collapse of the arteries supplying the fingers and toes. Blueness (cyanosis) may appear because the fingers or toes are not getting enough oxygen-rich blood. Finally, as the arterioles dilate (relax) and blood returns to the digits, redness (rubor) may occur.
During the attack, the fingers or toes may feel cold and numb as blood flow to them is interrupted. As the attack ends and blood flow returns, fingers or toes may throb and tingle. Typically, the blood flow to the skin will remain low until the skin is rewarmed. After warming, it usually takes 15 minutes to recover normal blood flow to the skin.
Most doctors find it fairly easy to diagnose Raynaud’s phenomenon but find it more difficult to identify the form of the disorder.
Physicians can now distinguish primary from secondary Raynaud’s phenomenon with a complete history and physical examination. Sometimes, special blood testing is needed. If the evaluation and special testing studies are normal, then the diagnosis of primary Raynaud’s phenomenon can be made and it is unlikely to change into a secondary form.
A few tests can help the doctor distinguish between primary and secondary Raynaud’s phenomenon. They are:
- Nailfold capillaroscopy. During this test, the doctor puts a drop of oil on the patient’s nailfolds, the skin at the base of the fingernail. The doctor then examines the nailfolds under a microscope to look for problems in the tiny blood vessels called capillaries. If the capillaries are enlarged or malformed, the patient may have a connective tissue disease.
- Antinuclear antibody (ANA) test. In this blood test, the doctor determines whether the body is producing special proteins called antibodies that are directed against the nuclei of the body’s cells. These abnormal antibodies are often found in people who have connective tissue diseases or other autoimmune disorders.
- Erythrocyte sedimentation rate (ESR or sed rate). This is a laboratory test for inflammation that measures how quickly red blood cells fall to the bottom of a test tube of unclotted blood. Rapidly descending cells (an elevated sed rate) indicate inflammation in the body.
The aims of treatment are to reduce the number and severity of attacks and to prevent tissue damage and loss of tissue in the fingers and toes. Most doctors are conservative in treating patients with primary Raynaud’s phenomenon because they do not get tissue damage. For these patients, doctors tend to recommend nondrug treatments before moving onto medications. For patients with secondary Raynaud’s phenomenon, medications are more often prescribed, because severe attacks with ulcers or tissue damage are more likely.
In the most severe cases, Raynaud’s causes ulcers and serious tissue damage that does not respond to medications. Doctors may use a surgical procedure called a digital sympathectomy with adventitial stripping (which involves removing the tissue and nerves around the blood vessels supplying the affected digits). Although this procedure may result in reducing symptoms and healing tissue, it only helps temporarily and therefore is reserved for difficult cases.
The most common treatments and self-help measures are described below.
Nondrug Treatments and Self-Help Measures
The following nondrug treatments and self-help measures can decrease the severity of Raynaud’s attacks and promote overall well-being.
- Take action during an attack. You can decrease both its length and severity by a few simple actions. The first and most important one is avoid the cold. Warming the body and the hands or feet is also helpful. If you’re outside and the weather is cold, go indoors. Run warm water over your fingers or toes or soak them in a bowl of warm water to warm them. If a stressful situation triggers the attack, get out of the stressful situation, if possible, and relax. Although biofeedback and similar nondrug methods are used, formal studies have suggested they are not helpful.
- Keep warm. It is important not only to keep the extremities warm, but also to avoid chilling any part of the body. Remember, a drop in the body’s core temperature triggers the attack. Shifting temperature (for example, rapidly moving from 90 degrees outside to a 70-degree air-conditioned room) and damp rainy weather are to be avoided. In cold weather, pay particular attention to dressing. Several layers of loose clothing, socks, hats, and gloves or mittens are recommended. A hat is important because a great deal of body heat is lost through the scalp. Keep feet warm and dry. Some people find it helpful to wear mittens and socks to bed during the winter. Chemical warmers, such as small heating pouches that can be placed in pockets, mittens, boots, or shoes, can give added protection during long periods outdoors.
People who have secondary Raynaud’s phenomenon should talk to their doctors before exercising outdoors in cold weather.
In warm weather, be aware that air conditioning also can trigger attacks. Setting the thermostat at a higher temperature or wearing a sweater indoors can help prevent an attack. Some people find it helpful to use insulated drinking glasses and to put on gloves before handling frozen or refrigerated foods.
- Do not smoke. The nicotine in cigarettes causes the skin temperature to drop, which may lead to an attack.
- Avoid aggravating medications such as vasconstrictors, which cause the blood vessels to narrow. Vasoconstrictors include beta-blockers, many cold preparations, caffeine, narcotics, some migraine headache medications, some chemotherapeutic drugs, and some blood pressure medications. Some studies also associate the use of estrogen with Raynaud’s phenomenon.
- Control stress. Because stress and emotional upsets may trigger an attack, particularly for people who have primary Raynaud’s phenomenon, learning to recognize and avoid stressful situations may help control the number of attacks. Many people have found that relaxation can help decrease the number and severity of attacks. Local hospitals and other community organizations, such as schools, often offer programs in stress management.
- Exercise regularly. Many doctors encourage patients who have Raynaud’s phenomenon—particularly the primary form—to exercise regularly. Most people find that exercise promotes overall well-being, increases energy level, helps control weight, and promotes cardiovascular fitness and restful sleep. Patients with Raynaud’s phenomenon should talk to their doctors before starting an exercise program.
- See a doctor. People with Raynaud’s phenomenon should see their doctors if they are worried or frightened about attacks or if they have questions about caring for themselves. They should always see their doctors if episodes occur only on one side of the body (one hand or one foot) and any time one results in sores or ulcers on the fingers or toes.
Treatment With Medications
People with secondary Raynaud’s phenomenon are more likely than those with the primary form to be treated with medications.1 Although there are no drugs approved by the Food and Drug Administration (FDA) for Raynaud’s, many doctors believe that the most effective and safest drugs for Raynaud’s phenomenon are calcium channel blockers. These drugs, which are used to treat high blood pressure, work by relaxing the smooth muscle and dilating the small blood vessels.
1 All medicines can have side effects. Some medicines and side effects are mentioned in this publication. Some side effects may be more severe than others. You should review the package insert that comes with your medicine and ask your health care provider or pharmacist if you have any questions about the possible side effects.
Some patients have found relief with alpha-receptor blockers, which are high blood pressure medications. Other medications known as phosphodiesterase (PDE)-5 inhibitors have also been used to treat people with Raynaud’s.
Patients may find that one drug works better than another. Some people may experience side effects that require stopping the medication. For other people, a drug may become less effective over time. Women of childbearing age should know that the medications used to treat Raynaud’s phenomenon may affect the growing fetus. Therefore, women who are pregnant or who might become pregnant should avoid taking these medications if possible. Interestingly, Raynaud’s phenomenon gets better or goes away during pregnancy.
In severe cases, medical procedures or surgeries may be indicated.
- Take action during an attack.
- Keep warm.
- Don’t smoke.
- Avoid aggravating medications.
- Control stress.
- Exercise regularly.
- See a doctor if questions or concerns develop.
Researchers are studying techniques to better diagnose Raynaud’s phenomenon and to predict and monitor its course and responsiveness to treatment. Scientists continue to evaluate the use of new treatments to improve blood flow for those who have Raynaud’s phenomenon.
Basic research continues on the molecular mechanisms behind Raynaud’s phenomenon, the anatomy of blood vessels, and possible genetic associations. Researchers in scleroderma and other connective tissue diseases are also investigating Raynaud’s phenomenon in relation to these diseases.
More information on research is available from the following websites:
- National Institutes of Health (NIH) Clinical Research Trials and You was designed to help people learn more about clinical trials, why they matter, and how to participate. Visitors to the website will find information about the basics of participating in a clinical trial, first-hand stories from clinical trial volunteers, explanations from researchers, and links on how to search for a trial or enroll in a research-matching program.
- ClinicalTrials.gov offers up-to-date information for locating federally and privately supported clinical trials for a wide range of diseases and conditions.
- NIH RePORTER is an electronic tool that allows users to search a repository of both intramural and extramural NIH-funded research projects from the past 25 years and access publications (since 1985) and patents resulting from NIH funding.
- PubMed is a free service of the U.S. National Library of Medicine that lets you search millions of journal citations and abstracts in the fields of medicine, nursing, dentistry, veterinary medicine, the health care system, and preclinical sciences.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institutes of Health
If you need more information about available resources in your language or another language, please visit our website or contact the NIAMS Information Clearinghouse at NIAMSinfo@mail.nih.gov.
National Heart, Lung, and Blood Institute
American College of Rheumatology
Lupus Foundation of America
Website: http://www.scleroderma.org (con información en español)
Scleroderma Research Foundation
Sjogren's Syndrome Foundation, Inc.
Antinuclear antibody (ANA). An abnormal protein called an autoantibody that is directed against the nuclei in the body’s cells. The presence of these autoantibodies in the body, particularly at high levels, often indicates a connective tissue disease.
Arteriole. A small branch of an artery (blood vessel that carries blood away from the heart) that leads into many smaller blood vessels near the skin’s surface.
Beta-blocker. A type of medication used to treat high blood pressure and other cardiovascular problems. The medications work by blocking the effects of stress hormones on the body’s beta receptors. This slows the nerve impulses that travel through the heart. As a result, your heart does not have to work as hard because it needs less blood and oxygen.
Biofeedback. A technique that uses electronic instruments to measure body functions and feed that information back to you, teaching you to bring involuntary body processes, such as blood pressure or skin temperature, under voluntary control.
Calcium channel blocker. A type of medication that affects the movement of calcium within the cells of the heart and blood vessels, thus relaxing the blood vessels and increasing the supply of blood and oxygen to the heart.
Connective tissue disease. Any of a group of diseases characterized by degeneration of collagen, a key component of connective tissues such as skin, muscles, tendons, and ligaments. Connective tissue diseases include scleroderma and lupus.
Cyanosis. A bluish discoloration of the skin and mucous membranes caused by a lack of oxygen in the blood.
Erythrocyte sedimentation rate (ESR or sed rate). A laboratory test for inflammation that measures how quickly red blood cells fall to the bottom of a test tube of unclotted blood. Rapidly descending cells (an elevated sed rate) indicate inflammation in the body.
Gangrene. Death and decay of part of the body caused by lack of blood supply.
Idiopathic. A word used to describe a disease for which the cause is not known.
Lupus. Short for systemic lupus erythematosus, an inflammatory disease of the connective tissue, which can affect the skin, joints, and internal organs.
Nailfold capillaroscopy. A test used to look for abnormalities of the tiny blood vessels called capillaries in the skin at the base of the fingernails. Enlarged or malformed capillaries may indicate a connective tissue disease.
Pallor. Paleness of the skin due to reduced blood flow.
Rubor. Redness of tissue. In Raynaud’s phenomenon, redness is caused by an increase in size of the small blood vessels of the affected extremities.
Sed rate. See erythrocyte sedimentation rate.
Sjögren’s syndrome. A condition in which the body’s immune system attacks the moisture-producing glands, resulting in uncomfortable and sometimes damaging dryness of tissues, particularly those of the eyes and mouth.
Vasospastic attack. An episode of the small blood vessels going into spasms, temporarily reducing blood flow to the extremities.
The NIAMS gratefully acknowledges the assistance of the following individuals in the preparation and review of previous versions of this publication: Elizabeth Gretz, Ph.D., NIAMS/NIH; Paul Plotz, M.D., NIAMS/NIH; Gabor Illei, M.D., Ph.D., NIDCR/NIH; Phillip J. Clements, M.D., University of California, Los Angeles, CA; Jay D. Coffman, M.D., Boston University Medical Center, Boston, MA; and Frederick M. Wigley, M.D., Johns Hopkins University School of Medicine, Baltimore, MD.
The mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the U.S. Department of Health and Human Services’ National Institutes of Health (NIH), is to support research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases; the training of basic and clinical scientists to carry out this research; and the dissemination of information on research progress in these diseases. The NIAMS Information Clearinghouse is a public service sponsored by the NIAMS that provides health information and information sources. Additional information can be found on the NIAMS website at www.niams.nih.gov.
For Your Information
This publication contains information about medications used to treat the health condition discussed here. When this publication was developed, we included the most up-to-date (accurate) information available. Occasionally, new information on medication is released.
For updates and for any questions about any medications you are taking, please contact
U.S. Food and Drug Administration
Toll free: 888-INFO-FDA (888-463-6332)
For additional information on specific medications, visit Drugs@FDA at http://www.accessdata.fda.gov/scripts/cder/daf/. Drugs@FDA is a searchable catalog of FDA-approved drug products.
For updates and questions about statistics, please contact
Centers for Disease Control and Prevention, National Center for Health Statistics
Toll free: 800-232-4636
This publication is not copyrighted. Readers are encouraged to duplicate and distribute as many copies as needed.
Additional copies of this publication are available from:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
National Institutes of Health
NIH Publication No. 15–4911